The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase-dependent signaling pathways
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The TEL/PDGFβR fusion protein is the product of the t(5;12) translocation in patients with chronic myelomonocytic leukemia. The TEL/PDGFβR is an unusual fusion of a putative transcription factor, TEL, to a receptor tyrosine kinase. The translocation fuses the amino terminus of TEL, containing the helix-loop-helix (HLH) domain, to the transmembrane and cytoplasmic domain of the PDGFβR. We hypothesized that TEL/PDGFβR self-association, mediated by the HLH domain of TEL, would lead to constitutive activation of the PDGFβR tyrosine kinase domain and cellular transformation. Analysis of in vitro -translated TEL/PDGFβR confirmed that the protein self-associated and that self-association was abrogated by deletion of 51 aa within the TEL HLH domain. In vivo , TEL/PDGFβR was detected as a 100-kDa protein that was constitutively phosphorylated on tyrosine and transformed the murine hematopoietic cell line Ba/F3 to interleukin 3 growth factor independence. Transformation of Ba/F3 cells required the HLH domain of TEL and the kinase activity of the PDGFβR portion of the fusion protein. Immunoblotting demonstrated that TEL/PDGFβR associated with multiple signaling molecules known to associate with the activated PDGFβR, including phospholipase C γ1, SHP2, and phosphoinositol-3-kinase. TEL/PDGFβR is a novel transforming protein that self-associates and activates PDGFβR-dependent signaling pathways. Oligomerization of TEL/PDGFβR that is dependent on the TEL HLH domain provides further evidence that the HLH domain, highly conserved among ETS family members, is a self-association motif.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Regenass, U., & Lydon, N. B. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2558 · Cited by 270
RetractedGene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours
Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., Rouleau, G., et al. (1992) · Nature · doi:10.1038/359162a0 · Cited by 1,907
Waterfield, M. D., Scrace, G. T., Whittle, N., Stroobant, P., Johnsson, A., Wasteson, Å., Westermark, B., Heldin, C.-H., Huang, J. S., & Deuel, T. F. (1983) · Nature · doi:10.1038/304035a0 · Cited by 1,616
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281
Golub, T. R., Barker, G. F., Lovett, M., & Gilliland, D. G. (1994) · Cell · doi:10.1016/0092-8674(94)90322-0 · Cited by 1,155
Self-citationBuchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Molecular cloning of gene sequences regulated by platelet-derived growth factor
Cochran, B. H., Reffel, A. C., & Stiles, C. D. (1983) · Cell · doi:10.1016/0092-8674(83)90037-5 · Cited by 945
Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.
Golub, T. R., Barker, G. F., Bohlander, S. K., Hiebert, S. W., Ward, D. C., Bray-Ward, P., Morgan, E., Raimondi, S. C., Rowley, J. D., & Gilliland, D. G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4917 · Cited by 704
Self-citationValius, M., & Kazlauskas, A. (1993) · Cell · doi:10.1016/0092-8674(93)90232-f · Cited by 647
Platelet-derived growth factor receptor signals.
Claesson-Welsh, L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)31591-6 · Cited by 561
Cited by
Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor
Heldin, C.-H., & Westermark, B. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1283 · Cited by 2,496
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Self-citationSignal transduction via platelet-derived growth factor receptors
Heldin, C.-H., Östman, A., & Rönnstrand, L. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00015-8 · Cited by 742
Roberts, K. G., Morin, R. D., Zhang, J., Hirst, M., Zhao, Y., Su, X., Chen, S.-C., Payne-Turner, D., Churchman, M. L., Harvey, R. C., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.005 · Cited by 714
Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G., & Druker, B. J. (1997) · Blood · doi:10.1182/blood.v90.12.4947 · Cited by 554
Self-citationPeeters, P., Raynaud, S. D., Cools, J., Wlodarska, I., Grosgeorge, J., Philip, P., Monpoux, F., Van Rompaey, L., Baens, M., Van den Berghe, H., et al. (1997) · Blood · doi:10.1182/blood.v90.7.2535 · Cited by 491
Kelly, L. M., Liu, Q., Kutok, J. L., Williams, I. R., Boulton, C. L., & Gilliland, D. G. (2002) · Blood · doi:10.1182/blood.v99.1.310 · Cited by 487
Self-citationCongenital Mesoblastic Nephroma t(12;15) Is Associated withETV6-NTRK3 Gene Fusion
Rubin, B. P., Chen, C.-J., Morgan, T. W., Xiao, S., Grier, H. E., Kozakewich, H. P., Perez-Atayde, A. R., & Fletcher, J. A. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65732-x · Cited by 437
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Azam, M., Seeliger, M. A., Gray, N. S., Kuriyan, J., & Daley, G. Q. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1486 · Cited by 411
Imatinib as a Paradigm of Targeted Therapies
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91001-9 · Cited by 370
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
Fröhling, S., Scholl, C., Gilliland, D. G., & Levine, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.010 · Cited by 353
Self-citationSpecificity within the ets Family of Transcription Factors
(1998) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60738-1 · Cited by 344
PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma
Östman, A. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.002 · Cited by 326
FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome
Xiao, S., Nalabolu, S. R., Aster, J. C., Ma, J., Abruzzo, L., Jaffe, E. S., Stone, R., Weissman, S. M., Hudson, T. J., & Fletcher, J. A. (1998) · Nature Genetics · doi:10.1038/ng0198-84 · Cited by 323
Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D. G., & Lodish, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509714102 · Cited by 316
Self-citationProtein tyrosine kinases and cancer
Kolibaba, K. S., & Druker, B. J. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00022-x · Cited by 291
Gotlib, J., Cools, J., Malone, J. M., Schrier, S. L., Gilliland, D. G., & Coutré, S. E. (2004) · Blood · doi:10.1182/blood-2003-06-1824 · Cited by 290
Self-citationFusion of ETV6 to Neurotrophin-3 Receptor TRKC in Acute Myeloid Leukemia With t(12;15)(p13;q25)
Eguchi, M., Eguchi-Ishimae, M., Tojo, A., Morishita, K., Suzuki, K., Sato, Y., Kudoh, S., Tanaka, K., Setoyama, M., Nagamura, F., et al. (1999) · Blood · doi:10.1182/blood.v93.4.1355 · Cited by 281
The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow
Wang, L. C., Swat, W., Fujiwara, Y., Davidson, L., Visvader, J., Kuo, F., Alt, F. W., Gilliland, D. G., Golub, T. R., & Orkin, S. H. (1998) · Genes & Development · doi:10.1101/gad.12.15.2392 · Cited by 277
Self-citationYolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL
Wang, L. C. (1997) · The EMBO Journal · doi:10.1093/emboj/16.14.4374 · Cited by 267
ARG tyrosine kinase activity is inhibited by STI571
Okuda, K., Weisberg, E., Gilliland, D. G., & Griffin, J. D. (2001) · Blood · doi:10.1182/blood.v97.8.2440 · Cited by 257
Self-citationPolymerization of the SAM domain of TEL in leukemogenesis and transcriptional repression
Kim, C. A., Phillips, M. L., Kim, W., Gingery, M., Tran, H. H., Robinson, M. A., Faham, S., & Bowie, J. U. (2001) · The EMBO Journal · doi:10.1093/emboj/20.15.4173 · Cited by 254
Ba/F3 cells and their use in kinase drug discovery
Warmuth, M., Kim, S., Gu, X.-J., Xia, G., & Adrián, F. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328011a25f · Cited by 240
Macdonald, D., Reiter, A., & Cross, N. C. P. (2002) · Acta Haematologica · doi:10.1159/000046639 · Cited by 210
“It is well established that tyrosine kinase fusion proteins, such as BCR-ABL and ETV6-PDGFRB, exist as dimers or multimers as a result of a homotypic interaction between specific domains of the partner gene, e.g. the BCR coiled-coil domain and the ETV6 pointed domain [ ,”
BackgroundAdvances in Understanding and Management of Myeloproliferative Neoplasms
Vannucchi, A. M., Guglielmelli, P., & Tefferi, A. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20009 · Cited by 207
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors
Sandberg, A. A., & Bridge, J. A. (2001) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00462-9 · Cited by 176
TEL Is a Sequence-specific Transcriptional Repressor
Lopez, R. G., Carron, C., Oury, C., Gardellin, P., Bernard, O., & Ghysdael, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.42.30132 · Cited by 174
Both TEL and AML-1 Contribute Repression Domains to the t(12;21) Fusion Protein
Fenrick, R., Amann, J. M., Lutterbach, B., Wang, L., Westendorf, J. J., Downing, J. R., & Hiebert, S. W. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.6566 · Cited by 162
The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells
Wai, D. H., Knezevich, S. R., Lucas, T., Jansen, B., Kay, R. J., & Sorensen, P. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203396 · Cited by 162
“The ETV6 HLH domain has been shown to be required for homodimerization and subsequent autophosphorylation in fusions with ABL in AML (Golub et al., 1996) and with PDGFRb in CMML (Carroll et al., 1996).”
BackgroundProteins of the ETS family with transcriptional repressor activity
Mavrothalassitis, G., & Ghysdael, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204045 · Cited by 153
“…to the transforming properties of these fusion oncoproteins in several cellular models and to their leukemogenic properties in animal models (Carroll et al., 1996; Golub et al., 1996; Jousset et al., 1997; Lacronique et al., 1997; Schwaller et al., 1998; Ritchie et al., 1999; Tomasson et…”
BackgroundNative interface of the SAM domain polymer of TEL
Tran, H. H., Kim, C. A., Faham, S., Siddall, M.-C., & Bowie, J. U. (2002) · BMC Structural Biology · doi:10.1186/1472-6807-2-5 · Cited by 42
“leads to constitutive activation of the tyrosine kinase domains, which leads in turn to cell transformation [10,12,18,19].”
Background(2024) · doi:10.1093/database/baae031 · Cited by 4
Orlic-Milacic, M., Rothfels, K., Matthews, L., Wright, A., Jassal, B., Shamovsky, V., Trinh, Q., Gillespie, M., Sevilla, C., Tiwari, K., et al. (2023) · doi:10.1101/2023.10.18.562964 · Cited by 4
Metadata
- Authors
- Carroll, M., Tomasson, M. H., Barker, G. F., Golub, T. R., & Gilliland, D. G.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1996-12-10
- Volume
- 93
- Issue
- 25
- Pages
- 14845-14850
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2117563665
- Cited by
- 268
- References
- 29
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.